Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res. 2018 Jun 15;24(12):2719-2731. doi: 10.1158/1078-0432.CCR-17-2494. Epub 2018 Feb 2.
With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular characteristics of a patient's tumor, and an increasing number of trials are genomically selected. Furthermore, multiple studies have demonstrated the benefit of therapies that are chosen based upon the molecular profile of a tumor. However, the rapid evolution of genomic testing platforms and emergence of new technologies make interpreting molecular testing reports more challenging. More sophisticated precision oncology decision support services are essential. This review outlines existing tools available for health care providers and precision oncology teams and highlights strategies for optimizing decision support. Specific attention is given to the assays currently available for molecular testing, as well as considerations for interpreting alteration information. This article also discusses strategies for identifying and matching patients to clinical trials, current challenges, and proposals for future development of precision oncology decision support. .
随着基因组学的日益普及，现在可以对高级癌症进行常规分析。治疗选择通常由患者肿瘤的分子特征指导，越来越多的试验是基于基因组选择的。此外，多项研究表明，根据肿瘤的分子谱选择治疗方法是有益的。然而，基因组检测平台的快速发展和新技术的出现使得解释分子检测报告变得更加具有挑战性。更复杂的精准肿瘤决策支持服务是必不可少的。本文概述了现有的医疗服务提供者和精准肿瘤团队可用的工具，并强调了优化决策支持的策略。特别关注目前可用于分子检测的检测方法，以及解释改变信息的注意事项。本文还讨论了确定和匹配患者参加临床试验的策略、当前的挑战以及对精准肿瘤决策支持未来发展的建议。
